LenioBio Announces a Scientific Advisory Board Composed of Experts within the Field of Biotechnology

Düsseldorf (ots) - LenioBio GmbH announces the appointment of Dr.
Lorenz M. Mayr, Prof. Govind Rao, and Prof. Stefan Schillberg to
LenioBio's Scientific Advisory Board (SAB). LenioBio is a German life
sciences start-up dedicated to the advancement of a transformative
technology for the discovery, development, and expression of
'difficult-to-produce' proteins unconstrained by the limitations of
the cell.

"We are thrilled to have such a strong group of people joining our
SAB" said Dr. Remberto Martis, CEO of LenioBio. "Each of these
individuals are preeminent experts in their own fields within the
space of biotechnology, and jointly they comprise the perfect
combination of knowledge and skills to provide invaluable guidance to
LenioBio's technological and strategic road map."

Dr. Mayr is the Chief Technology Officer at GE Healthcare Life
Sciences. Previously, he has held positions as Vice President &
Global Head at AstraZeneca, and Executive Director at Novartis
Pharmaceuticals, Bayer Pharmaceuticals, and the M.I.T./Whitehead
Institute in Cambridge, MA. Dr. Mayr says, "It is clear that LenioBio
has the potential to change the way proteins are produced in the
biopharmaceutical industry. After looking into various cell-free
platforms throughout my carrier, I had stopped expecting that a
cell-free protein expression technology could be a game changer; this
changed as soon as I came across the ALiCE platform. The broad
spectrum of protein classes that can be expressed by ALiCE in high
yields provides limitless potential for the production of complex
biopharmaceuticals. With the experienced management team and support
from the SAB, LenioBio is set to facilitate biopharmaceutical
development and production significantly for customers and partners
who want to leverage this technology."

Dr. Govind Rao is a Professor of Chemical & Biochemical
Engineering and the Director and founder of the Center of Advanced
Sensor Technology at the University of Maryland. The focus of Prof.
Rao's research has been the development of next-generation
biomanufacturing technology, in particular, producing protein-based
therapeutics at the point-of-care. Cell-free systems are the obvious
choice for such an approach, as proteins are produced in hours
compared with the several weeks needed by current cell-based
processes. Prof. Rao explains, "After applying cell-free protein
expression technologies in my research for the last 5 years, it is
clear to me that a high-yield eukaryotic system such as ALiCE has the
potential to finally allow the research community to make use of the
full potential of cell-free protein expression technology.
Furthermore, this technology has the potential to make medicines
available anywhere in the world and to serve the vast fraction of
humanity that currently has no access to affordable biologics"

Prof. Stefan Schillberg is Member of the Management Team at the
Fraunhofer Institute for Molecular Biology and Applied Ecology IME in
Aachen, Germany. His team, together with Corteva AgriScience,
developed a cell-free expression system capable of achieving a
productivity of 3 mg per mL before LenioBio took over the development
in 2017. "What is particularly exciting about the ALiCE platform is
that it is in the early stages of development compared with other
expression systems that have been around for decades. Therefore,
LenioBio has plentiful opportunities to advance the system
significantly further."

LenioBio launched the ALiCE platform in October 2018 as an
expression kit that outperforms its competitors in a single step.

Dr. Hákon Birgisson, Director of Business Development, concludes,
"We have been experiencing a lot of momentum as of late. Already in
the first three months from launch, most of the leading biotech
companies in the world have purchased an ALiCE kit or communicated
their interest in the ALiCE platform. Furthermore, we are finding an
increasing interest in LenioBio from investors as we are entering
into our next financial round."

Additional biographical information for the SAB members can be
found at https://www.leniobio.com/about/.

About LenioBio:

LenioBio GmbH is a life sciences start-up company committed to the
advancement of transformative technology for the discovery,
development and large-scale production of 'difficult-to-produce'
proteins, unconstrained by the limitations of the cell. LenioBio was
established as a legal entity in Germany in September 2016, with
offices in Dusseldorf and R&D and production labs in Aachen. For more
information about LenioBio, please visit our website at
www.leniobio.com.

Contact:
LenioBio Hákon Birgisson, Ph.D.
h.birgisson@leniobio.com
+49 211 890 940 30 401

Original-Content von: LenioBio GmbH, übermittelt durch news aktuell